UGCG (UDP-glucose ceramide glucosyltransferase) is a key enzyme that catalyzes the initial step of glycosphingolipid biosynthesis by transferring glucose from UDP-glucose to ceramide, producing glucosylceramide at the cytosolic surface of the Golgi 12. This glucosylceramide serves as the precursor for all glycosphingolipids, which are essential membrane components involved in cellular processes including signal transduction, membrane trafficking, and cell differentiation 3. UGCG plays critical roles in immune cell function, being selectively required for natural killer cell generation and CD8+ T cell expansion during viral infections through its regulation of cytotoxic granules 4. In cardiac tissue, UGCG is essential for maintaining β-adrenergic receptor trafficking and contractile capacity, with deficiency leading to heart failure 25. The enzyme is clinically significant as it is overexpressed in various cancers and correlates with multidrug resistance through its connection to MDR1 protein expression 3. UGCG inhibition has shown therapeutic potential in cancer treatment, particularly in overcoming resistance to lysosomal autophagy inhibition and MAPK pathway inhibitors in melanoma 67. The FDA-approved UGCG inhibitor eliglustat represents a promising therapeutic approach for cancer treatment 6.